Natco Pharma Launches Generic Version of Zortress® Immunosuppressant in U.S. Market
Natco Pharma Limited has announced the launch of Everolimus tablets, 1 mg, a generic version of Zortress® by Novartis, under the therapeutic class of immunosuppressant. The marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc., plans to launch the product immediately in the U.S. market. Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation. Breckenridge previously launched its Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths. Natco Pharma Limited is a Hyderabad-based company that develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products.
Key Highlights
- Natco Pharma launches Everolimus tablets, 1 mg, a generic version of Zortress® by Novartis.
- Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation.
- Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, is the marketing partner for the ANDA.
- Natco Pharma Limited is a Hyderabad-based company that develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products.
- Natco Pharma's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.